Medical device and healthcare company
Appears in 4 stories
Developer of the CardioMEMS HF System
Heart failure patients with Abbott's implanted pressure sensor will be able to see their own readings on a smartphone. The FDA approved the update on Oct. 5, 2026, and Abbott says the CardioGuide HF App will reach U.S. patients later in 2026.
Updated 3 hours ago
Exclusive U.S. commercializer of SimpleScreen CRC; operator of Cologuard franchise
Abbott began selling SimpleScreen CRC on September 30, giving average-risk Americans 45 and older a second FDA-approved blood test for colorectal cancer screening. The test reads cell-free DNA from a simple blood draw for signals associated with cancer. Abbott is betting it reaches people who never complete a colonoscopy or stool test.
Updated Sep 30
Expanding U.S. and global ablation portfolio
The Food and Drug Administration cleared Abbott's TactiFlex Duo, the first U.S. ablation catheter to combine pulsed field and radiofrequency energy. The device is designed for complex atrial fibrillation, a condition affecting about 10.5 million Americans.
Updated Sep 10
Pursuing leadless conduction system pacing (investigational)
For decades, defibrillators have saved lives by shocking dangerously fast rhythms back to normal, but the leads also pace the heart unnaturally and can cause damage over time. Medtronic's OmniaSecure lead is the first defibrillation lead that can pace through the heart's own electrical wiring, closely mimicking natural heartbeats. It has been cleared by the FDA for placement in the left bundle branch area.
Updated May 30
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
